Skip to main
MDXG
MDXG logo

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc. has revised its 2025 revenue estimate upward to $387.3 million, reflecting strong second-quarter results and a growing surgical business. In the second quarter, MiMedx reported revenue of $98.6 million, demonstrating a year-over-year growth of approximately 13%, primarily driven by its wound care portfolio and surgical offerings. Notably, the wound portfolio contributed $64.5 million, up 12% year-over-year, while the surgical sector increased by 15%, totaling $34.1 million, indicating robust demand for the company's regenerative biomaterial products.

Bears say

MiMedx Group Inc experienced a decline in gross margins, dropping from approximately 83% to 81% in 2Q25, which raises concerns regarding production efficiencies and product mix. Despite the company's long-term guidance suggesting low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin above 20%, previous performance indicates challenges in maintaining profitability. Furthermore, potential adverse changes in reimbursement rates from the Centers for Medicare & Medicaid Services (CMS) could negatively impact MiMedx's revenue and overall business viability.

MiMedx Group (MDXG) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 1 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.